阿加曲班联合依达拉奉治疗房颤合并脑栓塞的临床疗效观察

摘要

目的：分析探讨阿加曲班联合依达拉奉治疗房颤合并脑栓塞的临床疗效。方法将86例房颤合并脑栓塞患者随机分为两组，各43例；对照组患者实施低分子肝素治疗，观察组患者实施阿加曲班联合依达拉奉治疗，对比两组临床治疗效果。结果治疗前，两组NIHSS评分、Barthel指数差异无统计学意义（P＞0.05）；治疗后，两组上述两项指标均有所改善，但观察组改善效果更显著（P＜0.05）。观察组治疗总有效率（95.35%）高于对照组（55.81%），两组数据差异有统计学意义（P＜0.05）。结论房颤合并脑栓塞实施阿加曲班联合依达拉奉治疗效果显著。%Objective To investigate the clinical efficacy of argatroban combined with edaravone in the treatment of atrial fibrillation with cerebral embolism.Methods 86 patients with atrial fibrillation complicated with cerebral embolism patients were randomly divided into to two groups, 43 cases in each, control the implementation of low molecular weight heparin in the treatment group, patients in the observation group to implement of argatroban and argatroban combined with edaravone in treatment, compared to two groups of clinical therapeutic effect.Results Before treatment, the two groups of NIHSS score, Barthel index was not statistically significant (P>0.05). After treatment, the two groups were improved, but the improvement effect of the observation group was more signiifcant (P<0.05). The total effective rate in the observation group (95.35%) was higher than that in the control group (55.81%), and the difference between the two groups was statistically signiifcant (P<0.05). Conclusion Atrial fibrillation with cerebral embolism implementation of argatroban combined with edaravone treatment signiifcantly.